Quick Answer
Merck & Co., Inc. reported Diluted EPS of $7.28 per share for fiscal year 2025.
Merck & Co., Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $7.28 | +8.0% |
| 2024 | $6.74 | +4714.3% |
| 2023 | $0.14 | -97.5% |
| 2022 | $5.71 | +11.1% |
| 2021 | $5.14 | +84.9% |
| 2020 | $2.78 | -27.0% |
| 2019 | $3.81 | +64.2% |
| 2018 | $2.32 | +166.7% |
| 2017 | $0.87 | -38.3% |
| 2016 | $1.41 | -9.6% |
| 2015 | $1.56 | -61.7% |
| 2014 | $4.07 | +176.9% |
| 2013 | $1.47 | -26.5% |
| 2012 | $2.00 | -1.0% |
| 2011 | $2.02 | +621.4% |
| 2010 | $0.28 | -95.0% |
| 2009 | $5.65 | +55.6% |
| 2008 | $3.63 | +143.6% |
| 2007 | $1.49 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.32 | +87.1% | +31.8% |
| June 30, 2025 | $1.76 | -17.8% | -12.4% |
| March 31, 2025 | $2.01 | +7.5% | +62.1% |
| September 30, 2024 | $1.24 | -33.3% | -42.1% |
| June 30, 2024 | $2.14 | +191.1% | +14.4% |
| March 31, 2024 | $1.87 | +68.5% | +0.5% |
| September 30, 2023 | $1.86 | +45.3% | +179.1% |
| June 30, 2023 | -$2.35 | -251.6% | -311.7% |
- Merck & Co., Inc. showed an increase of +8.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2007–2025 period, Merck & Co., Inc.’s diluted eps has grown by 388.6% (from $1.49 per share to $7.28 per share).
- The most recent figure is from Merck & Co., Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: